Ou Silang, Vice President and China General Manager of US pharmaceutical major AbbVie (NYSE: ABBV), has decided to leave his post, according to an internal email. Intercon’s Senior Vice President Alberto Colzi will step in to take over temporarily until a successor is appointed.
Ou Silang’s Tenure and Background
Ou Silang has been at the helm of AbbVie’s China operations since June 2013, when the company officially entered the Chinese market. He holds a degree from the Chinese University of Hong Kong and has an extensive career in the pharmaceutical industry, having worked at Eli Lilly, Amgen, Merck, Sharp & Dohme (MSD), Bristol-Myers Squibb, and other notable companies. His roles have spanned from medical representative to product manager, director, and vice president. Before joining AbbVie, Mr. Ou served as Vice President and Head of Marketing and Strategy for China at MSD and Vice President of the China Hepatology Business Unit at BMS.
AbbVie’s Performance and Future Plans in China
AbbVie’s China unit achieved a growth rate exceeding 20% in 2022. The company has been focusing on in-licensing and domestic development in the China market. It expects to develop 3 new drugs and 7 new indications covering immunity, tumor, and ophthalmology before 2025, and aims to obtain more than 30 approvals before 2030 in China. This strategic commitment to the Chinese market highlights AbbVie’s long-term investment in the region.-Fineline Info & Tech
